BRPI1009461A8 - método não invasivo para avaliar a progressão da fibrose hepática - Google Patents

método não invasivo para avaliar a progressão da fibrose hepática

Info

Publication number
BRPI1009461A8
BRPI1009461A8 BRPI1009461A BRPI1009461A BRPI1009461A8 BR PI1009461 A8 BRPI1009461 A8 BR PI1009461A8 BR PI1009461 A BRPI1009461 A BR PI1009461A BR PI1009461 A BRPI1009461 A BR PI1009461A BR PI1009461 A8 BRPI1009461 A8 BR PI1009461A8
Authority
BR
Brazil
Prior art keywords
liver fibrosis
noninvasive method
assessing progression
assessing
progression
Prior art date
Application number
BRPI1009461A
Other languages
English (en)
Inventor
Cales Paul
Original Assignee
Centre Hospitalier Univ Dangers
Univ Angers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Univ Dangers, Univ Angers filed Critical Centre Hospitalier Univ Dangers
Publication of BRPI1009461A2 publication Critical patent/BRPI1009461A2/pt
Publication of BRPI1009461A8 publication Critical patent/BRPI1009461A8/pt
Publication of BRPI1009461B1 publication Critical patent/BRPI1009461B1/pt

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4713—Plasma globulins, lactoglobulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, e.g. Konjac gum, Locust bean gum, Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7052—Fibrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
BRPI1009461-0A 2009-03-19 2010-03-18 Métodos não invasivo para avaliar a progressão da fibrose hepática em um indivíduo e para avaliar se o indivíduo é formador de fibrose lenta, média ou rápida BRPI1009461B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16147409P 2009-03-19 2009-03-19
US61/161,474 2009-03-19
PCT/EP2010/053548 WO2010106140A1 (en) 2009-03-19 2010-03-18 Non-invasive method for assessing liver fibrosis progression

Publications (3)

Publication Number Publication Date
BRPI1009461A2 BRPI1009461A2 (pt) 2016-03-01
BRPI1009461A8 true BRPI1009461A8 (pt) 2017-09-12
BRPI1009461B1 BRPI1009461B1 (pt) 2019-08-20

Family

ID=42227782

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1009461-0A BRPI1009461B1 (pt) 2009-03-19 2010-03-18 Métodos não invasivo para avaliar a progressão da fibrose hepática em um indivíduo e para avaliar se o indivíduo é formador de fibrose lenta, média ou rápida

Country Status (7)

Country Link
US (2) US20120010824A1 (pt)
EP (1) EP2409154B1 (pt)
JP (1) JP5612067B2 (pt)
CN (2) CN107014996A (pt)
BR (1) BRPI1009461B1 (pt)
ES (1) ES2644725T3 (pt)
WO (1) WO2010106140A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2815416A1 (en) * 2010-10-21 2012-04-26 Vertex Pharmaceuticals Incorporated Biomarkers for hcv infected patients
US9036883B2 (en) * 2011-01-10 2015-05-19 The Regents Of The University Of Michigan System and methods for detecting liver disease
BR112013033595A2 (pt) * 2011-06-29 2017-01-24 Inner Mongolia Furui Medical Science Co Ltd aparelhagem e sistema de detecção de fibrose hepática
US9002656B2 (en) 2011-10-17 2015-04-07 Daxor Corporation Automated total body albumin analyzer
EP2873017B1 (en) * 2012-07-11 2021-09-01 University of Mississippi Medical Center Method for the detection and staging of liver fibrosis from image acquired data
WO2014109708A1 (en) 2013-01-08 2014-07-17 Agency For Science, Technology And Research A method and system for assessing fibrosis in a tissue
EP2772882A1 (en) * 2013-03-01 2014-09-03 Universite D'angers Automatic measurement of lesions on medical images
EP2930515A1 (en) * 2014-04-08 2015-10-14 Universite D'angers Prognostic tests for hepatic disorders
CN105092855B (zh) * 2014-05-23 2017-10-03 杭州普望生物技术有限公司 一种用于肝纤维化和肝硬化检测的试剂盒
EP2980753A1 (en) 2014-08-01 2016-02-03 Centre Hospitalier Universitaire d'Angers Method for displaying easy-to-understand medical images
WO2016061621A1 (en) * 2014-10-21 2016-04-28 Jeffrey Gary Peter Liver test
CN104887243B (zh) * 2015-07-02 2017-08-01 郭璐 一种血小板指数测评快查计算滑动尺
US11605460B2 (en) 2016-01-08 2023-03-14 Centre Hospitalier Universitaire D'angers Multi-targeted fibrosis tests
CN109111451B (zh) * 2017-06-26 2020-08-11 广东东阳光药业有限公司 二氢嘧啶类化合物及其在药物中的应用
CN107368689B (zh) * 2017-07-31 2019-11-19 董云鹏 人体数据采集和分析系统
EP3698139A1 (en) * 2017-10-16 2020-08-26 Biopredictive Method of prognosis and follow up of primary liver cancer
CN110237263B (zh) * 2018-03-07 2022-06-17 昆山新蕴达生物科技有限公司 HFn包载阿霉素的方法及其产物
CN108931645A (zh) * 2018-07-26 2018-12-04 北京大学第医院 一种hcv清除后肝纤维化评估系统及评估方法
CN109473175A (zh) * 2018-11-07 2019-03-15 中山大学附属第三医院（中山大学肝脏病医院） 一种针对肝纤维化的非侵入性血清学评分模型及其设计方法
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
TWI685854B (zh) * 2019-02-01 2020-02-21 中國醫藥大學附設醫院 肝纖維化評估模型、肝纖維化評估系統及肝纖維化評估方法
WO2021011369A1 (en) * 2019-07-12 2021-01-21 Primegen Biotech, Llc Methods of treatment using encapsulated cells
EP4106791A1 (en) * 2020-02-19 2022-12-28 Hepion Pharmaceuticals, Inc. Use of cyclosporine analogues for treating fibrosis
CN111783792B (zh) * 2020-05-31 2023-11-28 浙江大学 一种提取b超图像显著纹理特征的方法及其应用
CN112250769A (zh) * 2020-09-30 2021-01-22 四川携光生物技术有限公司 Ftcd和cyp2d6融合蛋白及其构建方法、应用
WO2024102976A1 (en) * 2022-11-11 2024-05-16 The Board Of Regents Of The University Of Texas System Molecular signatures to predict long-term liver fibrosis progression

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6738001A (en) 2000-04-28 2001-11-20 Bayer Aktiengesellschaft Assessment of liver fibrosis scoring with serum marker algorithms
US7668661B2 (en) * 2000-04-28 2010-02-23 Siemens Healthcare Diagnostics Inc. Liver disease-related methods and systems
GB0202213D0 (en) 2002-01-31 2002-03-20 Imp College Innovations Ltd Methods
US6986995B2 (en) 2002-02-28 2006-01-17 Prometheus Laboratories, Inc. Methods of diagnosing liver fibrosis
WO2006129513A1 (ja) 2005-05-30 2006-12-07 Ajinomoto Co., Inc. 肝疾患評価装置、肝疾患評価方法、肝疾患評価システム、肝疾患評価プログラムおよび記録媒体
ES2543160T3 (es) 2003-01-14 2015-08-17 Vib Vzw Un marcador de suero para medir fibrosis hepática
US20070197424A1 (en) * 2003-09-16 2007-08-23 Friedman Scott L Glatiramer acetate for use as an immuno-modulatory agent
FR2870348B1 (fr) * 2004-05-14 2010-08-27 Univ Angers Methode pour diagnostiquer la presence et/ou la severite d'une pathologie hepathique chez un sujet
WO2006003654A2 (en) 2004-07-01 2006-01-12 Medical Research Fund Of Tel Aviv Sourasky Medical Center Methods and kits for predicting liver fibrosis progression rate in chronic hepatitis c patients
EP1626280B1 (en) * 2004-08-12 2007-02-14 Roche Diagnostics GmbH Method for diagnosing liver fibrosis
WO2007021860A2 (en) * 2005-08-11 2007-02-22 Bayer Healthcare Llc QUANTITATIVE ASSAYS FOR PDGFR-β IN BODY FLUIDS
WO2008152070A1 (en) * 2007-06-14 2008-12-18 Vib Vzw Diagnostic test for the detection of early stage liver cancer
US20100049029A1 (en) 2008-08-20 2010-02-25 Hong Kong Applied Science And Technology Research Institute Co., Ltd. Piezoelectric magnetic resonance elastograph (mre) driver system

Also Published As

Publication number Publication date
EP2409154A1 (en) 2012-01-25
JP5612067B2 (ja) 2014-10-22
CN102439456A (zh) 2012-05-02
US20170337322A1 (en) 2017-11-23
EP2409154B1 (en) 2017-08-02
ES2644725T3 (es) 2017-11-30
CN107014996A (zh) 2017-08-04
BRPI1009461A2 (pt) 2016-03-01
WO2010106140A1 (en) 2010-09-23
JP2012520995A (ja) 2012-09-10
US10861582B2 (en) 2020-12-08
BRPI1009461B1 (pt) 2019-08-20
US20120010824A1 (en) 2012-01-12
CN102439456B (zh) 2016-11-02

Similar Documents

Publication Publication Date Title
BRPI1009461A8 (pt) método não invasivo para avaliar a progressão da fibrose hepática
ES2858225T8 (es) Procedimiento para producir elementos estructurales templados
BRPI1013601A2 (pt) método para fabricação de uma emulsão de poliuretano reativa
BRPI1015541A2 (pt) kit e método para a preparação de uma solução de degarelix
BR112013018900A2 (pt) conjuntos para uma estrutura
BRPI1012638A2 (pt) métodos e intermediários para preparar agentes farmacêuticos
BRPI1013082A2 (pt) marcadores de risco para enfermidade cardiovascular
BR112012002102A2 (pt) composição farmaceutica e metodo para preparar uma composição farmaceutica
BR112013029498A8 (pt) método para produzir um suíno geneticamente modificado
BR112012006620A2 (pt) método para fabricação de uma cobertura de engate de cilindro
BR112012031033A2 (pt) composição de si--g-poliolefina e processo para fazer uma composição de si-g-poliolefina
BRPI0922490A2 (pt) Método para produção de beta-santaleno
BR112012016908A2 (pt) linhagens e métodos para a produção de metionina
BR112014000167A8 (pt) método para manufatura de uma casca de confeitaria
BR112012014162A2 (pt) método de fabricação de uma nanomanta
BR112013005984A2 (pt) composição lubrificante e método para fazer uma composição lubrificante
BR112013014479A2 (pt) método melhorado e kit para determinar a gravidade e progressão da doença periodontal
BR112012021703A2 (pt) método e equipamento para a preparação de um novo lipossomo
BR112012010615A2 (pt) estrutura de colméia e método para formar uma estrutura de colméia
BR112013015563A2 (pt) método para produzir uma amina terciária
BR112013005986A2 (pt) processo para preparar uma composição derivada de estolídeo e composição derivada de estolídeo
BRPI1010841A2 (pt) método para a fabricação de fluoroalquilnitrilas
BR112013014581A2 (pt) método para a fabricação de um diorgano-di-halossilano
BRPI0915937A2 (pt) método para glicosilação de um lipídeo
BRPI1009145A2 (pt) método para a fabricação de derivado de benzodiazepina

Legal Events

Date Code Title Description
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/03/2010, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/03/2010, OBSERVADAS AS CONDICOES LEGAIS